OBJECTIVES: To investigate mycophenolate mofetil (MMF) plasma levels and impact on acute graft versus host disease (aGvHD) after stem cell transplantation (SCT). METHODS: SCT patients (n = 14) with aGvHD (>/= II) receiving MMF (1-3 g/d) in addition to cyclosporine, prednisolone, and methotrexate for aGvHD prophylaxis were investigated. Plasma levels of mycophenolic acid (MPA) and its glucuronide metabolite (MPAG) were determined by high-performance liquid chromatography. RESULTS: Overall median steady state pre-dose plasma MPA concentration was 0.47 mg/L and increased within 75 min after administration to 1.64 mg/L. In comparison to patients with skin aGvHD, patients with gut aGvHD had lower MPA concentrations, both pre-dose (p = 0.16) and after 75 min, (p = 0.02). All 7 patients with skin aGvHD but only 2 patients with gut aGvHD responded to MMF. Overall, the pre-dose plasma MPA concentration was significantly (p = 0.007) greater in responders (n = 9) than in non-responders (n = 5). CONCLUSION: MMF seems to be an effective treatment for aGvHD in SCT patients particular in those patients without gut involvement.
OBJECTIVES: To investigate mycophenolate mofetil (MMF) plasma levels and impact on acute graft versus host disease (aGvHD) after stem cell transplantation (SCT). METHODS: SCT patients (n = 14) with aGvHD (>/= II) receiving MMF (1-3 g/d) in addition to cyclosporine, prednisolone, and methotrexate for aGvHD prophylaxis were investigated. Plasma levels of mycophenolic acid (MPA) and its glucuronide metabolite (MPAG) were determined by high-performance liquid chromatography. RESULTS: Overall median steady state pre-dose plasma MPA concentration was 0.47 mg/L and increased within 75 min after administration to 1.64 mg/L. In comparison to patients with skin aGvHD, patients with gut aGvHD had lower MPA concentrations, both pre-dose (p = 0.16) and after 75 min, (p = 0.02). All 7 patients with skin aGvHD but only 2 patients with gut aGvHD responded to MMF. Overall, the pre-dose plasma MPA concentration was significantly (p = 0.007) greater in responders (n = 9) than in non-responders (n = 5). CONCLUSION:MMF seems to be an effective treatment for aGvHD in SCT patients particular in those patients without gut involvement.
Authors: Betty K Hamilton; Ying Liu; Michael T Hemmer; Navneet Majhail; Olle Ringden; Dennis Kim; Luciano Costa; Robert Stuart; Amin Alousi; Joseph A Pidala; Daniel R Couriel; Mahmoud Aljurf; Joseph H Antin; Christopher Bredeson; Jean-Yves Cahn; Mitchell Cairo; Sung Won Choi; Christopher Dandoy; Robert Peter Gale; Usama Gergis; Peiman Hematti; Yoshihiro Inamoto; Rammurti T Kamble; Margaret MacMillan; David I Marks; Eneida Nemecek; Taiga Nishihori; Ayman Saad; Bipin N Savani; Jeff Schriber; Sachiko Seo; Gérard Socié; Takanori Teshima; Leo F Verdonck; Edmund K Waller; Mona Wirk; Stephen R Spellman; Mukta Arora; Saurabh Chhabra Journal: Biol Blood Marrow Transplant Date: 2019-05-31 Impact factor: 5.742
Authors: Luisa Giaccone; Jeannine S McCune; Michael B Maris; Theodore A Gooley; Brenda M Sandmaier; John T Slattery; Scott Cole; Richard A Nash; Rainer F Storb; George E Georges Journal: Blood Date: 2005-09-06 Impact factor: 22.113
Authors: Pamala A Jacobson; Jiayin Huang; Juan Wu; Miae Kim; Brent Logan; Amin Alousi; Michael Grimley; Javier Bolaños-Meade; Vincent Ho; John E Levine; Daniel Weisdorf Journal: Biol Blood Marrow Transplant Date: 2010-03 Impact factor: 5.742
Authors: Cara L McDermott; Brenda M Sandmaier; Barry Storer; Hong Li; Donald E Mager; Michael J Boeckh; Meagan J Bemer; Jennifer Knutson; Jeannine S McCune Journal: Biol Blood Marrow Transplant Date: 2013-05-06 Impact factor: 5.742
Authors: P Jacobson; S F El-Massah; J Rogosheske; A Kerr; J Long-Boyle; T DeFor; C Jennissen; C Brunstein; J Wagner; M Tomblyn; D Weisdorf Journal: Bone Marrow Transplant Date: 2009-01-19 Impact factor: 5.483
Authors: T Furlong; P Martin; M E D Flowers; F Carnevale-Schianca; R Yatscoff; T Chauncey; F R Appelbaum; H J Deeg; K Doney; R Witherspoon; B Storer; K M Sullivan; R Storb; R A Nash Journal: Bone Marrow Transplant Date: 2009-04-20 Impact factor: 5.483